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determine if this difference existed in our group of patients,
of those patients requiring a flap the majority did receive an
omental transposition.
The results of these studies, although limited by the small
number of patients evaluated, illustrate that vacuum therapy
is an important treatment tool for the thoracic surgeon faced
with poststernotomy mediastinitis. Moreover, its use also
decreases the need for additional surgical reconstruction
with vascularized flaps. The results from our study of 102
patients support these findings. Vacuum therapy proved to
be an important adjunct to the treatment of poststernotomy
mediastinitis. The overall incidence of poststernotomy me-
diastinitis at our institution is between 1% and 1.5%. The
wound vacuum system can be used either in combination
with a vascular flap or as a primary therapy following
debridement, which in turn allows secondary healing to
proceed. The depth of the sternal infection influences the
role of the wound vacuum, as either sole therapy for more
superficial wounds or as adjuvant therapy for deeper
wounds. Among those patients receiving vacuum therapy,
43 required vascularized flaps; however, 53 required no
additional procedures except for wound debridement and
secondary closure with the VAC system. Although a con-
trolled randomized study would be necessary to determine if
the wound vacuum device significantly lowered mortality
and morbidity compared with historical treatment modali-
ties, the data from this study support the role of the wound
vacuum not only as an effective treatment tool but also to
significantly lower overall mortality.
In conclusion, VAC is a useful asset in the treatment of
poststernotomy mediastinitis. It may be used effectively
before primary closure or as a preparation for secondary
closure with vascularized tissue.
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Discussion
Dr James W. Long (Salt Lake City, Utah). Dr Wolfe, you and
your colleagues have made some very important contributions
with a novel therapy. First, this is clearly the largest experience
with vacuum-assisted closure for mediastinitis, 96 patients, and
before this 15 maximum. Second, your mortality outcomes in this
series are quite impressive at 3.7%. Third, 55% of your patients
were able to get by without vascular flap reconstruction. Obviously
there are some important things that have been learned here. There
are some challenges that are left, one of which that is not entirely
clear from this paper is what role vacuum-assisted closure may be
contributing. Your study design is primarily observational, with no
statistically useful control group. You have a second group of
small sample size, 6 patients, but not really characterized very
well. One has to consider the possibility that your improved
outcomes may not be due entirely vacuum-assisted closure. Cer-
tainly before this therapy results have been progressively improv-
ing. Even in your own institution in 1996 there was a 29%
incidence of mediastinitis and by 1999 it is reduced to 10.5% when
you used pectoralis flaps, and down to 4.8% with omental flaps
without this therapy, quite close to the mortality results you had
with this therapy. In the absence of a formal control group, we are
not given a lot of information, either, to help us judge this histor-
ically. The question I have for you is: Do you believe that vacuum-
assisted closure therapy has been responsible for your improved
mortality?
Dr Domkowski. Thank you, Dr Long, for reviewing our paper
and for your comments and question. You are right, it is an
observational and a retrospective analysis of vacuum-assisted clo-
sure. The way to do it would be a prospective trial in which we
would randomize patients either to traditional treatment followed
by vascular flap therapy if it were appropriate versus vacuum-
assisted. However, as this has been introduced to our institution,
and obviously there is some bias involved, Dr Wolfe and I were
very impressed with their initial results of vacuum-assisted ther-
apy. In a significant number of patients, it has reduced the need for
a second intervention (ie, omental or pectoral flap). We do believe
that the use of this device is in large part responsible for the
reduction in mortality. I think it is important to remember that the
additional benefit, while it does reduce mortality, also saved many
patients from an additional procedure, because with debridement
in the operating room, with the infection going down to the bone,
sometimes the wires would need to be tightened or a few taken out
and then the vacuum-assisted device put in place. It is really quite
remarkable that the physiology behind this vacuum does promote
stimulation of granulation tissue, at least subjectively, again, to be
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much greater than that which would be observed in traditional wet
to dry dressing changes.
Dr Long. While having 55% of the patients not require vas-
cular flap reconstruction may be good news, in an era when early
omental flap reconstruction has been shown to have good results,
it would be nice to know that vacuum-assisted closure provides
some clear and distinct advantage before exposing patients to what
may be a delay in getting to flap reconstruction, at least a delay that
45% of your patients were exposed to. In your series I think there
were 27 days of hospitalization, which in this era may seem a bit
long. Were there any significant differences in time to discharge
for the vacuum-assisted closure only versus those that were fol-
lowed by flaps, and how would that rack up against those going
directly to a vascular flap?
Dr Domkowski. You are right; 27 days is long, and that is in
part related to intravenous antibiotic therapy that we kept our
patients on, especially if they grew out a specific bug. Many of
these were polymicrobial. Sometimes these therapies were able to
be covered at home with a home health nurse. Other times the
situation with the sternum was such that Dr Wolfe and I wanted to
keep a close eye on the progression of healing. To answer your
question, we did not see a difference between the 2 groups, and
with the use of the vacuum-assisted closure we were able to avoid
quite a few flaps, but that in turn may delay hospitalization a bit
longer because we wanted to give these patients a chance to
declare themselves. It also had to do with the degree of infection
at presentation and their comorbidities, which would also dictate
when this patient needs to go directly to flap rather than waiting for
a while with the vacuum-assisted closure.
Dr Long. Besides duration of hospitalization, time to closure of
the wound certainly would also be a factor. Could you tell us about
how much time it takes for these 55% of your patients with
vacuum-assisted closure only to have their wounds fully close?
Dr Domkowski. It varies, between 3 and 6 weeks, depending
on the depth of infection and whether all or some of the wires
needed to be removed.
Dr Long. One final observation and question for you. Obvi-
ously one way to shorten that course perhaps is to predict those
ahead of time who might well end up needing omental flaps; 45%
in your series. You did do an analysis of the severity of medias-
tinitis and inferred in the paper that the deeper wounds may
predispose people to the need for flaps, but I do not think you went
beyond that. Could you tell us what you have learned that may help
you make an early determination as to which ones will need flaps?
Dr Domkowski. Specifically those patients who have some-
times late presentation will require all wires to be removed at the
time of debridement and who do not have an initial good response
to the wound vacuum. Again this is a subjective thing, but looking
at these wounds every 2 to 3 days when the dressing is changed,
there are some patients who have a significant number of comor-
bidities that did not progress as you would expect with vacuum
therapy and those patients will tend to flap sooner rather than later.
We do have a preference for omental flaps, and if we see that they
are not progressing, Dr Wolfe will perform an omental flap.
Surgery for Acquired Cardiovascular Disease Domkowski et al
390 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
A
CD
